Ocular Pain - Pipeline Review, H2 2011

Global Markets Direct
November 28, 2011
30 Pages - SKU: GMD6691631
Ocular Pain - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Ocular Pain - Pipeline Review, H2 2011', provides an overview of the Ocular Pain therapeutic pipeline. This report provides information on the therapeutic development for Ocular Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ocular Pain. 'Ocular Pain - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Ocular Pain.
  • A review of the Ocular Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Ocular Pain pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Ocular Pain.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Ocular Pain therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.



More Drug Discovery reports by Global Markets Direct

Polio - Pipeline Review, H2 2014 by Global Markets Direct
Polio - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Polio - Pipeline Review, H2 2014’, provides an overview of the Polio’s therapeutic pipeline.This report provides comprehensive ...
Klebsiella Pneumoniae Infections - Pipeline Review, H2 2014 by Global Markets Direct
Klebsiella Pneumoniae Infections - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Klebsiella Pneumoniae Infections - Pipeline Review, H2 2014’, provides an overview of the Klebsiella Pneumoniae ...
African Trypanosomiasis - Pipeline Review, H2 2014 by Global Markets Direct
African Trypanosomiasis - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘African Trypanosomiasis - Pipeline Review, H2 2014’, provides an overview of the African Trypanosomiasis’s therapeutic pipeline.This ...
Acromegaly - Pipeline Review, H2 2014 by Global Markets Direct
Acromegaly - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Acromegaly - Pipeline Review, H2 2014’, provides an overview of the Acromegaly’s therapeutic pipeline.This report provides comprehensive ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 500  
    Global Site License  USD 1,500  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!